Is Lyka Labs overvalued or undervalued?

As of 22 September 2025, the valuation grade for Lyka Labs has moved from fair to attractive, indicating a more favorable outlook. The company is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 47.14, an EV to EBITDA of 21.84, and a PEG ratio of 0.08, which suggests strong growth potential relative to its price.
In comparison to its peers, Lyka Labs stands out with a higher PE ratio than Sun Pharma (34.24) and a significantly lower PEG ratio than Divi's Lab (1.86), indicating that Lyka Labs may offer better value for growth. Additionally, while the stock has underperformed the Sensex year-to-date, its long-term performance over five years shows a remarkable return of 435.51%, reinforcing the attractiveness of its current valuation.